Øster Farimagsgade 5 opg. Q, Postboks 2099
1014 København K
Individuel and social aspects of medication taking
More and more people are using pharmaceuticals, not only to prevent, manage or treat illness, but also to sustain health. My primary research interest concerns the individual and social effects of pharmaceutical treatment. I primarily use qualitative, ethnographic research method to explore matters of medication taking in everyday life, and document analysis to investigate changes in the understanding of the role of medicines in society. My research is situated at the cross-section of Science and Technology Studies (STS), social pharmacy and medical anthropology.
Elderly and Antidepressants
Project title: Decision Aid for the prescription of antidepressants among frail seniors
My post doc project concerns the prescription and use of antidepressants for the treatment of mild-moderate depression among frail seniors. In the project, I explore the distributed decision-making processes in relation to the prescription of antidepressants and hereby seek to understand the role of the pharmaceuticals in the management of mental health. The empirical data is used to develop a decision aid to support user-involvement in the decision or decline of antidepressants. The homecare team in Albertslund municipality is partner in the project. The project is financed by the Velux Foundation's project pool on Elderly and Medication.
The Routinization of statins in Denmark
Title of PhD Dissertation: A Matter of Course. An Ethnographic Assemblage of the Routinization of Statins in Denmark
My PhD study was part of the interdisciplinary CPHU financed project; LIFESTAT - Living with statins, which focused on the prevention of cardiovascular disease (CVD) with cholesterol-lowering pharmaceuticals, statins. In the dissertation, I explore the transformation of statins from scientifically contested to standard of care by mapping how the field of preventive medicine is shaped by a variety of human actors, technologies and logics. I argue that pharmaceutical prevention of cardiovascular risk has become 'a matter of course'; a self-evident solution to the problem of being at risk. This framing of pharmaceutical prevention influences on the individual and clinical aspects of care.
As part of the project, I am co-authoring the site: www.kolesteroldialog.dk